News
Eli Lilly's orforglipron missed weight loss targets in a Phase 3 trial, but strong Q2 results and raised guidance highlight ...
Detailed price information for Novo Nordisk A/S ADR (NVO-N) from The Globe and Mail including charting and trades.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback